Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress.1
强生公司（纽交所：JNJ）今天宣布来自第1b/2期OrigAMI-1研究的新数据，显示RYBREVANt（amivantamab-vmjw）联合化疗（mFOLFOX6 [FOLFOX]或FOLFIRI）在之前未接受抗表皮生长因子受体（EGFR）治疗的RAS/BRAF野生型（WT）转移性结肠癌（mCRC）患者中表现出有希望的快速和持久的抗肿瘤活性。这些数据是在2024年欧洲医学肿瘤学会（ESMO）大会上以迷你口头报告的形式呈现的。1